Closing out the year with warm celebrations in Palo Alto! We are grateful for the heartfelt contributions from everyone at Bitterroot Bio, whether near or far. Here's to the collective efforts that made this year special! #BitterrootBio#HeartfeltCheers
Exciting news from our team at AHA: BRB-002 shows promise in preventing atherogenesis in ApoE deficient mice, an important step forward in our mission to innovate therapies for CVD patients.
#bitterrootbio#cardiovascularresearch#innovation#CD47
We presented new data today at #AHA23.
BRB-002 demonstrated efficacy in a model of established atherosclerosis and prevented atherogenesis in ApoE deficient mice.
Looking forward to advancing BRB-002 to human clinical trials next year!
#hearthealth#athero@BitterrootBio
The Bitterroot Bio teams came together in Maine for our annual offsite. We delved into our team's #curiosity, explored breakthrough science, discussed the patient experience, and of course, indulged in some delicious LOBSTAH! #CardiovascularResearch#Innovation#BitterrootBio
🧪 Autoimmune and inflammatory diseases treatment biotech startup MozartTherapeutics raised $25M in Series A extension funding from @pfizer Ventures, @abbvie Ventures, ARCH Venture Partners, @SofinnovaVC, and others.
(5/12)
🧬 San Diego-based gene therapy startup Kate Therapeutics emerged from stealth with a $51M Series A round co-led by @BioWestlake and Versant Ventures, with backing from @UFVentures and @OUP_VC
(4/12)
Bitterroot Bio hit the trails of Palo Alto and the suburbs of Boston in honor of Global Running Day! Every mile contributing to the American Heart Association…what a fun annual event!
#cardiovascularhealth#bitterrootbio#AHA#companywellness